Panelists report that the AUGMENT-101 trial demonstrated meaningful clinical benefits of menin inhibitors in ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response ...

Overall, the past decade has seen a remarkable transformation in the treatment landscape for AML. These advancements have led to improved outcomes for many patients, particularly those with previously ...

Although this can happen sometimes with AML, such as with the genetic syndromes discussed in Risk Factors for Acute Myeloid Leukemia (AML), inherited mutations are not a common cause of AML. Most DNA ...

Understanding the fundamental molecular mechanisms underlying normal hematopoiesis and AML pathogenesis can aid the development of novel and effective targeted therapies.

Disruption of normal ‘hematopoietic’ development or the differentiation of stem cells into various blood types, can result in blood cancers like acute myeloid leukemia (AML). Despite ...

Hypoxia‐inducible transcription factor HIF2α contributes to acute myeloid leukemia (AML) pathogenesis by taking part to the molecular network that suppresses differentiation of leukemic blasts alon ...

Acute myeloid leukemia (AML) survival rates vary significantly by age, health status, and genetics, among other factors. Learn more here.

AML treatment side effects can include nausea, fatigue, hair loss, and a higher risk of infections. Most of the effects are short-term.